Jubilant Radiopharma is a global leader in the field of nuclear medicine, operating as a specialized division of Jubilant Pharmova Limited, a major integrated pharmaceutical company headquartered in Noida, India. While the parent entity is rooted in India, Jubilant Radiopharma maintains a massive operational footprint in North America, functioning through two primary business verticals: Radiopharmaceuticals (manufacturing) and Radiopharmacies (distribution).
The company?s core mission is "Improving Lives Through Nuclear Medicine." It distinguishes itself by controlling the entire value chain of diagnostic and therapeutic isotopes. Unlike competitors that may only manufacture drugs or only run pharmacies, Jubilant Radiopharma does both. It develops and manufactures complex radioactive agents at its facility in Montreal, Canada (formerly known as Jubilant DraxImage), and distributes them through the second-largest network of nuclear pharmacies in the United States.
Jubilant Radiopharma serves hospitals, imaging centers, and cardiology clinics, providing the critical "tracers" required for Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) scans. These scans are essential for diagnosing cancer, heart disease, and neurological disorders.
The Radiopharmaceuticals Division (Manufacturing)
Headquartered in Kirkland (Montreal), Quebec, this division (formerly Jubilant DraxImage Inc.) is the R&D and manufacturing engine of the company. It specializes in the production of "cold kits" (non-radioactive lyophilized powders) and radioactive generators.
Cardiac PET Imaging: RUBY-FILL?
The company?s flagship product in the cardiac space is RUBY-FILL?, a cutting-edge Rubidium-82 (Rb-82) generator and elution system.
* Function: It is used for Positron Emission Tomography (PET) imaging of the myocardium (heart muscle).
* Technology: The system generates Rubidium-82, a short-lived positron emitter, from Strontium-82.
* Advantage: Unlike older systems, RUBY-FILL offers automated quality control and flexible dosing options, allowing physicians to assess myocardial perfusion (blood flow) with high precision under rest and stress conditions. This helps detect coronary artery disease (CAD).
Thyroid Care: I-131 Solutions
Jubilant Radiopharma is a dominant player in the diagnosis and treatment of thyroid conditions using Radioiodine (I-131).
* HICON?: A concentrated Sodium Iodide I-131 solution used for the treatment of hyperthyroidism (Graves' disease) and thyroid carcinoma.
* Diagnostic Capsules: The company manufactures I-131 capsules used to evaluate thyroid function (uptake scans) before determining therapeutic doses.
SPECT Imaging Products (Cold Kits)
The company produces a wide range of lyophilized (freeze-dried) kits. These "cold" vials are shipped to pharmacies, where they are reconstituted with radioactive Technetium-99m (Tc-99m) to create active diagnostic agents.
* DRAXIMAGE? MAA (Macroaggregated Albumin): The gold standard for lung perfusion imaging. It is used in conjunction with ventilation agents to diagnose Pulmonary Embolism (PE).
* DRAXIMAGE? DTPA (Pentetate): Used for lung ventilation imaging and renal (kidney) function scans.
* DRAXIMAGE? MDP-25 (Medronate): A bone imaging agent used to detect metastasis (cancer spread to bones), fractures, and infections.
* DRAXIMAGE? Sestamibi: A generic myocardial perfusion imaging agent widely used for cardiac stress tests.
* DRAXIMAGE? Exametazime: Used for labeling white blood cells (leukocytes) to detect intra-abdominal infections.
The Radiopharmacies Division (Distribution)
Through the acquisition of Triad Isotopes, Jubilant Radiopharma established the second-largest radiopharmacy network in the United States. This division bridges the gap between the manufacturing plant and the patient's bedside.
Network Scale: The company operates over 45 nuclear pharmacies across the US, serving more than 1,800 healthcare customers.
Service Model: These pharmacies operate like specialized compounding labs. They receive "cold kits" and radioactive isotopes (like Tc-99m generators) in the early morning hours. Nuclear pharmacists then compound, quality-check, and dispense patient-specific unit doses.
Logistics: The division employs a massive fleet of medical couriers who deliver these time-sensitive radioactive doses to hospitals and clinics just minutes before the scheduled patient scan.
Open Formulary: Unlike some competitors that restrict access to proprietary products, Jubilant Radiopharmacies maintains an "open formulary" approach, distributing products from various manufacturers to ensure hospitals have access to whatever agent they prefer.
Innovation and Strategic Focus
Jubilant Radiopharma is actively pivoting towards Theranostics?the integration of therapy and diagnostics.
* Partnerships: They utilize their pharmacy network to distribute novel agents for other biotech firms, such as prostate cancer imaging agents (PSMA-PET).
* Smart-Fill?: The company developed proprietary dispensing technology to automate the preparation of I-131 capsules, enhancing safety for pharmacists by reducing radiation exposure during handling.
Please note: This information is generated by AI. For legal use, verify with company sources.
